Varian Medical joins embolic therapy tech dev ABK Biomedical ’ s $30m Series B

Varian Medical (NYSE:VAR) has joined a $30 million Series B round of financing for embolic therapy tech developer ABK Biomedical. Palo Alto, Calif.-based Varian Medical Systems led the round alongside F-Prime Capital, Halifax, Nova Scotia-based ABK Biomedical said. “ABK has a unique approach to address a large unmet need for patients with non-resectable liver tumors. This technology is aligned with our goal of delivering innovative solutions in cancer care,” Varian strategy &biz dev VP Gregory Sorensen said in a press release. “We are impressed with the ABK Biomedical team and believe the company has an outstanding product platform with the potential to make a significant impact on the lives of patients with malignant liver tumors,” F-Prime Capital partner Dr. Ketan Patel said in a prepared release. Funds from the round will support continued development of the Eye90 microspheres, designed for transarterial radiation therapy and intended to treat liver tumors, and its Easi-Vue microspheres, intended for the bland embolic treatment of hypervascular tumors. ABK Biomedical said that funds will support R&D, manufacturing and a clinical development program intended to support regulatory submission for both the Eye90 and Easi-Vue, the company said. “Our thought-leading physician partners and advisors see tremendous opportunities to improve procedural and oncologic outcomes for patients suffering from non-resectable liver tumors. The ABK platfo...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Oncology Radiosurgery/Radiation therapy Wall Street Beat abkbiomedical Varian Medical Systems Source Type: news

Related Links:

Conditions:   Cancer;   Palliative Radiotherapy Interventions:   Radiation: Lattice stereotactic body radiation therapy;   Procedure: Peripheral blood Sponsor:   Washington University School of Medicine Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Glioblastoma is the most common and aggressive brain tumour in adults with a median overall survival of only 14  months after standard therapy with radiation therapy (IR) and temozolomide (TMZ). In a novel mult...
Source: Journal of Experimental and Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Research Source Type: research
Innovations in artificial intelligence (AI) are driving a new industrial revolution, and as a result, the medical radiation sciences is experiencing transformational, open, beneficial, yet disruptive changes. Many studies have already been published on specific frontline examples where AI will improve cancer care, but discussions of how AI will change the medical radiation sciences and its associated professions at the systems level have been comparatively sparse. In this article, the system-level implications of AI on the medical radiation sciences are discussed, and recommendations are made on how professionals in this f...
Source: Journal of Medical Imaging and Radiation Sciences - Category: Radiology Authors: Tags: Commentary Source Type: research
Conclusions: altogether, our data suggest that resistance to EGFR inhibition combined with radiotherapy in HNSCC may depend on tumor HIF-2 expression and underline the urgent need to develop novel HIF-2 targeted treatments.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Conclusion: Radiation therapy for nCRT could downstage clinically suspected nodal metastasis. However, such therapy was ineffective when used to treat nodes that were not suspicious for metastasis. Because significant numbers of residual metastases were identified irrespective of coverage by the radiation field, lymphadenectomy should be performed to ensure complete removal of residual nodal metastases after nCRT. PMID: 31624713 [PubMed]
Source: Korean Journal of Thoracic and Cardiovascular Surgery - Category: Cardiovascular & Thoracic Surgery Tags: Korean J Thorac Cardiovasc Surg Source Type: research
Publication date: January 2020Source: Radiation Physics and Chemistry, Volume 166Author(s): Fang-Yu Liu, Zhi-Wei Dong, Hui-Bin Yang, Hong-Yun ShiAbstractEven with advanced inverse intensity modulated radiation therapy (IMRT) technique, the optimization of treatment plans remains a time-consuming task and the outcome is highly influenced by the experience of the planner and time pressure. Automated treatment planning is a current hot topic and new frontier in radiotherapy, which is expected to minimize the above problems. The quality and efficacy of the IMRT plans generated by the Auto-Planning module of the Pinnacle3 treat...
Source: Radiation Physics and Chemistry - Category: Physics Source Type: research
A radiation therapy (RT) treatment that combines radiation with chemotherapy...Read more on AuntMinnie.comRelated Reading: Intelerad to launch enterprise software at RANZCR 2019 RANZCR issues final version of ethical AI guidelines RANZCR praises government pledge to support MRI access RANZCR proposes ethical guidelines for AI Virtual reality may help plan, guide glioma resection
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
ConclusionThis survey was an informative trial to understand the verification status of patient-specific IMRT QA measurements for prostate cancer. In most institutions, the point dose measurement and dose distribution differences met the desired criteria.
Source: Reports of Practical Oncology and Radiotherapy - Category: Cancer & Oncology Source Type: research
ConclusionsThe study showed that radiotherapy causes skin barrier dysfunction in all patients independently of clinical radiodermatitis. The biophysical features of this dysfunction can precede clinical symptoms and they can be assessed by non-invasive and objective methods.
Source: Reports of Practical Oncology and Radiotherapy - Category: Cancer & Oncology Source Type: research
ConclusionsFor radiotherapy recipients, early Medicaid expansion was associated with decreased percent uninsured, particularly among low education counties, and earlier stage diagnoses for screenable cancers. Thus, early Medicaid expansion may improve access to care and decrease disparities for radiotherapy recipients.
Source: Practical Radiation Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Liver | Medical Devices | Radiation Therapy | Urology & Nephrology